McCoy said the company has a "well-developed" quality system and a dedicated group of engineers and scientists who relentlessly pursue improvement. Defibrillators and pacemakers, he said, aspire to a 99% reliability level over the course of several years, and tens of thousands of people are alive today because of these therapies. Yet Scott + Scott's investigation has yielded information that the Guidant failure rate of 1% is based only upon the number of devices returned to the Company for inspection. According to a source, results from internal, unpublished post-market clinical trials show a failure rate that suggests 8% is closer to the truth. This is due to the fact that most devices are not returned to Guidant when a patient dies and that the elderly who die rarely undergo an autopsy, facts ignored by the Company when information was provided to the public. Insider trading is now calculated at over $60 million.